Global Cancer Cases Poised to Double by 2050, WHO Warns

The global burden of cancer is set to increase dramatically, with new cases projected to nearly double by 2050, according to a stark warning from the World Health Organization (WHO). The report indicates that the disease, already the second leading cause of death worldwide, could affect a vast majority of the global population at some point in their lives.

Current estimates place annual cancer deaths at around 10 million, with over 20 million new cases diagnosed each year. The WHO warns that without significant intervention, this number of new cases could skyrocket to 35 million by 2050. Lung cancer is expected to remain the deadliest form of the disease.

While medical advancements have improved survival rates for many, the WHO report emphasizes a growing disparity in outcomes based on geographical location and socioeconomic status. In high-income countries, the five-year survival rate for certain cancers, like breast and childhood cancers, exceeds 85%. However, this figure plummets to below 45% in low-income nations, underscoring a critical gap in healthcare access.

The report also highlights systemic challenges impeding effective cancer care. Twenty-three countries are reported to lack basic radiotherapy facilities, and a significant two-thirds of nations have not integrated cancer care into their universal health coverage schemes. The financial strain of treatment is immense, with up to 90% of patients in some regions forced to abandon care due to costs, leading to cancer being a primary driver of medical bankruptcy globally.

The WHO's projections suggest that if current trends persist, an alarming 92% of people worldwide will be impacted by cancer by 2050, either through personal diagnosis or that of a close family member. In response, the organization is calling for a concerted, people-centered approach. This includes integrating cancer prevention, diagnosis, and treatment services into universal healthcare systems, bolstering support networks for patients and their caregivers, and fostering research and innovation to improve treatment accessibility.

The report also touches upon ongoing efforts in cancer vaccine development, noting that numerous countries are exploring various approaches. Russia, for instance, is actively developing personalized mRNA cancer vaccines, with two experimental therapies – Neooncovac for melanoma and Oncopept for colorectal cancer – having received clearance for clinical use and showing promising immune responses in early trials. Other nations, including the United States, the United Kingdom, Cuba, and China, are also engaged in similar research and development.